Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 201–300 of 946

Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review)
Wang, Y., Lin, W., Zhuang, X., Wang, X., He, Y., Li, L., & Lyu, G. (2024) · Oncology Reports · doi:10.3892/or.2024.8705 · Cited by 46
Therapeutic applications of PARP inhibitors in ovarian cancer
Xie, H., Wang, W., Xia, B., Jin, W., & Lou, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110204 · Cited by 47
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
Tomášová, K., Čumová, A., Šeborová, K., Horak, J., Koucká, K., Vodičková, Ľ., Václavíková, R., & Vodička, P. (2020) · Cancers · doi:10.3390/cancers12071713 · Cited by 47
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
Gralewska, P., Gajek, A., Marczak, A., Mikuła, M., Ostrowski, J., Śliwińska, A., & Rogalska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249715 · Cited by 45
Molecular Pathology of Human Papilloma Virus-Negative Cervical Cancers
Yoshida, H., Shiraishi, K., & Kato, T. (2021) · Cancers · doi:10.3390/cancers13246351 · Cited by 45
Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis
Wu, N., Zhang, X., Fang, C., Zhu, M., Wang, Z., Jian, L., Tan, W., Wang, Y., Li, H., Xu, X., et al. (2024) · Research · doi:10.34133/research.0371 · Cited by 44
The role of PARP inhibitors in BRCA mutated pancreatic cancer
Chi, J., Chung, S. Y., Parakrama, R. Y., Fayyaz, F., Jose, J., & Saif, M. W. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211014818 · Cited by 47
In silico modeling and molecular docking insights of kaempferitrin for colon cancer-related molecular targets
Govindarasu, M., Ganeshan, S., Ansari, M. A., Alomary, M. N., Alyahya, S. A., Alghamdi, S. A., Almehmadi, M. M., Rajakumar, G., Thiruvengadam, M., & Vaiyapuri, M. (2021) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2021.101319 · Cited by 44
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Sun, C., Cao, W., Qiu, C., Li, C., Dongol, S., Zhang, Z., Dong, R., Song, K., Yang, X., Zhang, Q. H., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0844-0 · Cited by 43
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
Tao, L., Zhou, Y., Pan, X., Luo, Y., Qiu, J., Zhou, X., Chen, Z., Li, Y., Xu, L., Zhou, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42850-x · Cited by 44
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158304 · Cited by 46
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Shapiro, G. I., Kristeleit, R. S., Burris, H. A., LoRusso, P. M., Patel, M. R., Drew, Y., Giordano, H., Maloney, L., Watkins, S. P., Goble, S. M., et al. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.575 · Cited by 47
Self-citation
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Azim, H. A., Ghosn, M. G., Oualla, K., & Kassem, L. M. H. (2019) · The Breast Journal · doi:10.1111/tbj.13713 · Cited by 43
Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications
Romero, I., Leskelä, S., Perez‐Mies, B., Poveda, A. M., & Palacios, J. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2020.02.001 · Cited by 46
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
van Wijk, L. M., Vermeulen, S., Meijers, M., van Diest, M. F., ter Haar, N. T., de Jonge, M. M., Solleveld‐Westerink, N., van Wezel, T., van Gent, D. C., Kroep, J. R., et al. (2020) · Cancers · doi:10.3390/cancers12102805 · Cited by 45
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
Guffanti, F., Alvisi, M. F., Anastasia, A., Ricci, F., Chiappa, M., Llop‐Guevara, A., Serra, V., Fruscio, R., Degasperi, A., Nik‐Zainal, S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01609-1 · Cited by 43
From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
Mouw, K. W., & Konstantinopoulos, P. A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0017-x · Cited by 43
Self-citation
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
Fleury, H., Carmona, E., Morin, V. G., Meunier, L., Masson, J., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2016) · Oncotarget · doi:10.18632/oncotarget.10308 · Cited by 42
PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
Wang, Y., Zheng, K., Xiong, H., Huang, Y., Chen, X., Zhou, Y., Qin, W., Su, J., Chen, R., Qiu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762989 · Cited by 42
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code
Cammarata, G., Barraco, N., Giusti, I., Gristina, V., Dolo, V., & Taverna, S. (2022) · Cancers · doi:10.3390/cancers14143404 · Cited by 42
SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses
Zhu, S., Hou, J., Gao, H., Hu, Q., Kloeber, J. A., Huang, J., Zhao, F., Zhou, Q., Luo, K., Wu, Z., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.003 · Cited by 42
The role of PARP inhibitor combination therapy in ovarian cancer
Hockings, H., & Miller, R. E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231173183 · Cited by 44
Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus
Zhou, J., Li, J., Serafim, R. B., Ketchum, S., Ferreira, C. G., Liu, J. C., Coe, K. A., Price, B. D., & Yusufzai, T. M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky128 · Cited by 41
Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer
Giampaolino, P., Corte, L. D., Foreste, V., Vitale, S. G., Chiofalo, B., Cianci, S., Zullo, F., & Bifulco, G. (2019) · Minerva Medica · doi:10.23736/s0026-4806.19.06086-5 · Cited by 41
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Loverix, L., Vergote, I. B., Busschaert, P., Vanderstichele, A., Venken, T., Boeckx, B., Harter, P., Brems, H., Nieuwenhuysen, E. V., Pignata, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.020 · Cited by 41
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer
Rosario, S. R., Long, M. D., Chilakapati, S. R., Gomez, E. C., Battaglia, S., Singh, P. K., Wang, J., Wang, K., Attwood, K. M., Hess, S. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54565-8 · Cited by 40
Association between DNA damage repair gene somatic mutations and immune‐related gene expression in ovarian cancer
Tian, W., Shan, B., Zhang, Y., Ren, Y., Liang, S., Zhao, J., Zhao, Z., Wang, G., Zhao, X., Peng, D., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2849 · Cited by 40
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Ewing, A., Meynert, A. M., Churchman, M., Grimes, G. R., Hollis, R. L., Herrington, C. S., Rye, T., Bartos, C., Croy, I., Ferguson, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4068 · Cited by 40
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
Guffanti, F., Mengoli, I., & Damia, G. L. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1405361 · Cited by 39
DNA Repair Deficiency and Immunotherapy Response
Mouw, K. W., & D’Andrea, A. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2425 · Cited by 39
Self-citation
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 40
Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course
Takaya, H., Nakai, H., Sakai, K., Nishio, K., Murakami, K., Mandai, M., & Matsumura, N. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.013 · Cited by 39
Mitochondrial superoxide contributes to oxidative stress exacerbated by DNA damage response in RAD51-depleted ovarian cancer cells
Xu, L., Wu, T., Lu, S., Hao, X., Qin, J., Wang, J., Zhang, X., Liu, Q., Kong, B., Gong, Y., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101604 · Cited by 39
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Konstantinopoulos, P. A., Cheng, S., Supko, J. G., Polak, M. M., Wahner-Hendrickson, A. E., Ivy, S. P., Bowes, B., Sawyer, H., Basada, P., Hayes, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01664-8 · Cited by 39
Self-citation
Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Hurley, R. M., McGehee, C. D., Nesic, K., Correia, C., Weisskittel, T., Kelly, R. L., Venkatachalam, A., Hou, X., Pathoulas, N. M., Meng, X. W., et al. (2021) · NAR Cancer · doi:10.1093/narcan/zcab028 · Cited by 40
USP37 regulates DNA damage response through stabilizing and deubiquitinating BLM
Wu, C., Chang, Y., Chen, J., Su, Y., Li, L., Chen, Y., Li, Y., Wu, J., Huang, J., Zhao, F., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab842 · Cited by 38
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
Chiang, Y., Lin, P., & Cheng, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675972 · Cited by 38
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Liu, M., Tayob, N., Penter, L., Sellars, M., Tarren, A. Y., Chea, V. A., Carulli, I. P., Huang, T., Li, S., Cheng, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2834 · Cited by 38
Self-citation
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
Konstantinopoulos, P. A., & Matulonis, U. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1314 · Cited by 37
Self-citation
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073871 · Cited by 39
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer
Blanc‐Durand, F., Yaniz‐Galende, E., Llop‐Guevara, A., Genestie, C., Serra, V., Herencia-Ropero, A., Klein, C., Berton, D., Lortholary, A. H., Dohollou, N., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.01.026 · Cited by 36
Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer
Zeng, S., Wang, X., & Yang, H. (2024) · Military Medical Research · doi:10.1186/s40779-024-00580-1 · Cited by 41
The structure of ends determines the pathway choice and Mre11 nuclease dependency of DNA double-strand break repair
Liao, S., Tammaro, M., & Yan, H. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw274 · Cited by 36
DNA Repair: Translation to the Clinic
Minten, E. V., & Yu, D. S. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.02.007 · Cited by 36
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient Cells
Färkkilä, A., Rodríguez, A., Oikkonen, J., Gulhan, D., Nguyen, H. Q., Domínguez, J., Ramos, S., Mills, C. E., Pérez‐Villatoro, F., Lazaro, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2912 · Cited by 39
Self-citation
RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
van Wijk, L. M., Nilas, A. B., Vrieling, H., & Vreeswijk, M. P. G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2020102 · Cited by 41
The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks
van Wijk, L. M., Kramer, C. J. H., Vermeulen, S., ter Haar, N. T., de Jonge, M. M., Kroep, J. R., de Kroon, C. D., Gaarenstroom, K. N., Vrieling, H., Bosse, T., et al. (2021) · Cancers · doi:10.3390/cancers13122994 · Cited by 36
Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: Talazoparib
McCann, K. E. (2019) · Future Oncology · doi:10.2217/fon-2018-0751 · Cited by 35
The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing
Tao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 35
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies
Mittempergher, L. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0526-9 · Cited by 35
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor
Teng, Q., Lei, Z., Wang, J., Yang, Y., Wu, Z., Acharekar, N., Zhang, W., Yoganathan, S., Pan, Y., Wurpel, J. N. D., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101028 · Cited by 34
Advances in hybrid hydrogel design for biomedical applications: innovations in drug delivery and tissue engineering for gynecological cancers
Chang, H., Wei, H., Qi, Y., Ding, S., Li, H., & Si, S. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10064-0 · Cited by 34
Prediction of therapy response in ovarian cancer: Where are we now?
Bairi, K. E., Amrani, M., Kandhro, A. H., & Afqir, S. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1313190 · Cited by 34
Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer
Sun, H., Cao, D., Ma, X., Yang, J., Peng, P., Yu, M. Y., Zhou, H., Zhang, Y., Li, L., Huo, X., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00839 · Cited by 34
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
Shan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 35
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
Khella, C. A., Mehta, G. A., Mehta, R. N., & Gatza, M. L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020149 · Cited by 35
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
Cash, T., Fox, E., Liu, X., Minard, C. G., Reid, J. M., Scheck, A. C., Weigel, B. J., & Wetmore, C. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29065 · Cited by 34
Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance
Goel, N., Foxall, M. E., Scalise, C. B., Wall, J., & Arend, R. C. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0992 · Cited by 34
The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
Kim, H., Ahn, S., Kim, H.-S., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03781-6 · Cited by 34
A catalog of numerical centrosome defects in epithelial ovarian cancers
Morretton, J., Simon, A., Herbette, A., Barbazán, J., Gonzalez, C. P., Cosson, C., Mboup, B., Latouche, A., Popova, T. G., Kieffer, Y., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215670 · Cited by 34
Implementing precision cancer medicine in the genomic era
Chen, H., Bonneville, R., & Roychowdhury, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.009 · Cited by 34
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
Miller, R. E., Elyashiv, O., El-Shakankery, K. H., & Ledermann, J. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s272199 · Cited by 34
Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
Macerelli, M., Ganzinelli, M., Gouédard, C., Broggini, M., Garassino, M. C., Linardou, H., Damia, G. L. M., & Wiesmüller, L. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.05.004 · Cited by 33
Constitutional Mosaic Epimutations – a hidden cause of cancer?
Lønning, P. E., Eikesdal, H. P., Løes, I. M., & Knappskog, S. (2019) · Cell Stress · doi:10.15698/cst2019.04.183 · Cited by 33
EMT Transcription Factor ZEB1 Represses the Mutagenic POLθ-Mediated End-Joining Pathway in Breast Cancers
Prodhomme, M. K., Pommier, R. M., Franchet, C., Fauvet, F., Bergoglio, V., Brousset, P., Morel, A., Brunac, A., Devouassoux‐Shisheboran, M., Pétrilli, V., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2626 · Cited by 33
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial
Callens, C., Vaur, D., Soubeyran, I., Rouleau, É., Just, P., Guillerm, E., Golmard, L., Goardon, N., Sévenet, N., Cabaret, O., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa193 · Cited by 33
Multi-Omics Data Fusion for Cancer Molecular Subtyping Using Sparse Canonical Correlation Analysis
Lin, Q., Wang, W., Wu, T., Zhu, L., He, L., & Wang, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.607817 · Cited by 36
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
Czyż, M., Toma, M. M., Gajos-Michniewicz, A., Majchrzak, K., Hoser, G., Szemraj, J., Nieborowska-Skorska, M., Cheng, P. F., Gritsyuk, D., Levesque, M. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12270 · Cited by 33
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
Hirschl, N., Leveque, W., Granitto, J., Sammarco, V., Fontillas, M., & Penson, R. T. (2024) · Cancers · doi:10.3390/cancers16050932 · Cited by 32
Mechanisms of PARP inhibitor resistance in ovarian cancer
Kubalanza, K., & Konecny, G. E. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000600 · Cited by 33
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
da Costa, A. A. B. A., do Canto, L. M., Larsen, S. J., Ribeiro, A. R. G., Stecca, C., Petersen, A. H., Aagaard, M. M., Brot, L. D., Baumbach, J., Baiocchi, G., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5622-4 · Cited by 32
Ferroptosis: mechanism, immunotherapy and role in ovarian cancer
Guo, K., Lu, M., Bi, J., Yao, T., Gao, J., Ren, F., & Zhu, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410018 · Cited by 33
Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
Otsuka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094409 · Cited by 31
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises
Skorda, A., Bay, M. L., Hautaniemi, S., Lahtinen, A., & Kallunki, T. (2022) · Cancers · doi:10.3390/cancers14246257 · Cited by 31
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Molin, G. Z. D., Omatsu, K., Sood, A. K., & Coleman, R. L. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918778483 · Cited by 30
Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers
Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30
Targeting Non-Oncogene Addiction for Cancer Therapy
Chang, H. R., Jung, E., Cho, S., Jeon, Y.-J., & Kim, Y. (2021) · Biomolecules · doi:10.3390/biom11020129 · Cited by 30
The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma
Machino, H., Kaneko, S., Komatsu, M., Ikawa, N., Asada, K., Nakato, R., Shozu, K., Dozen, A., Sone, K., Yoshida, H., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02992-4 · Cited by 30
The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer
Wang, Y., Huang, Z., Li, B., Liu, L., & Huang, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863541 · Cited by 30
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Flynn, M. J., & Ledermann, J. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.13 · Cited by 31
BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers
Loboda, A. P., Adonin, L., Zvereva, S. D., Pestov, N. B., Guschin, D. Y., Korneenko, T. V., Telegina, A. V., Kondratieva, O. K., Frolova, S. E., & Barlev, N. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054982 · Cited by 32
Defects in homologous recombination repair behind the human diseases: FA and HBOC
Katsuki, Y., & Takata, M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0221 · Cited by 32
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
Yan, S., Frank, D. O., Son, J., Hannan, K. M., Hannan, R. D., Chan, K. T., Pearson, R. B., & Sanij, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010210 · Cited by 31
The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features
Santoro, A., Angelico, G., Travaglino, A., Inzani, F. S., Spadola, S., Pettinato, A., Mazzucchelli, M., Bragantini, E., Macciò, L., & Zannoni, G. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104603 · Cited by 29
Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma
Vigneron, N., Vernon, M., Meryet‐Figuière, M., Lambert, B., Briand, M., Louis, M.-H., Krieger, S., Joly, F., Lheureux, S., Blanc‐Fournier, C., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvz013 · Cited by 29
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Pérez‐Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3156 · Cited by 29
Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events
Mackay, D. R., Howa, A. C., Werner, T. L., & Ullman, K. S. (2017) · Journal of Cell Science · doi:10.1242/jcs.203513 · Cited by 31
Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells
Rauch, A., Carlstedt, A., Emmerich, C., Mustafa, A. M., Göder, A., Knauer, S. K., Linnebacher, M., Heinzel, T., & Krämer, O. H. (2018) · Oncotarget · doi:10.18632/oncotarget.25600 · Cited by 29
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer
Konstantinopoulos, P. A., & Matulonis, U. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.006 · Cited by 29
Self-citation
Targeting the DNA damage response in cancer
Guffanti, F., Chiappa, M., & Damia, G. L. M. (2024) · MedComm · doi:10.1002/mco2.788 · Cited by 30
Niraparib for the treatment of ovarian cancer
Kanjanapan, Y., Lheureux, S., & Oza, A. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297423 · Cited by 30
Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
Moes-Sosnowska, J., Rzepecka, I. K., Chodzynska, J., Dansonka‐Mieszkowska, A., Szafron, L. M., Balabas, A., Lotocka, R., Sobiczewski, P., & Kupryjańczyk, J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1579955 · Cited by 29
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer
Kanakkanthara, A., Huntoon, C. J., Hou, X., Zhang, M., Heinzen, E. P., O’Brien, D. R., Oberg, A. L., Weroha, S. J., Kaufmann, S. H., & Karnitz, L. M. (2019) · Nature Communications · doi:10.1038/s41467-019-12610-x · Cited by 28
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays
Morice, P., Coquan, E., Weiswald, L., Lambert, B., Vaur, D., & Poulain, L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01295-z · Cited by 29
Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
Xu, J., Shen, Y., Wang, C., Tang, S., Hong, S., Lü, W., Xie, X., & Cheng, X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00638-2 · Cited by 28
Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients
Zong, H., Zhang, J., Xu, Z., Pan, J.-N., Wang, R., Han, J., Jiang, M., Ren, R., Zang, L., Wang, H., et al. (2022) · Journal of Cancer · doi:10.7150/jca.65650 · Cited by 29
Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition
Li, Y., Cen, Y., Fang, Y., Tang, S., Li, S., Ren, Y., Zhang, H., Lü, W., & Xu, J. (2022) · ACS Nano · doi:10.1021/acsnano.2c04956 · Cited by 28
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
Biegała, Ł., Gajek, A., Marczak, A., & Rogalska, A. (2023) · Cells · doi:10.3390/cells12071038 · Cited by 28
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Li, J., Zhi, X., Chen, S., Shen, X., Chen, C., Yuan, L., Guo, J., Meng, D., Chen, M., & Yao, L. (2020) · PubMed Central · Cited by 27
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 28

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks